Oral Oncology
Volume 45, Issue 12 , Pages 1044-1050, December 2009

Malignant salivary gland tumors and cyclo-oxygenase-2: A histopathological and immunohistochemical analysis with implications on histogenesis

  • Sharon Akrish

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Rambam Medical Center, 6 Ha’Aliya Street, P.O. Box 9602, Haifa 31096, Israel
    • Department of Pathology, Rambam Medical Center, 6 Ha’Aliya Street, P.O. Box 9602, Haifa 31096, Israel
    • Corresponding Author InformationCorresponding author. Address: Department of Oral and Maxillofacial Surgery, Rambam Medical Center, 6 Ha’Aliya Street, P.O. Box 9602, Haifa 31096, Israel. Tel.: +972 4 610 0012; fax: +972 4 610 0013.
  • ,
  • Micha Peled

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Rambam Medical Center, 6 Ha’Aliya Street, P.O. Box 9602, Haifa 31096, Israel
    • Technion-Faculty of Medicine, P.O. Box 9649, Haifa 31096, Israel
  • ,
  • Ofer Ben-Izhak

      Affiliations

    • Department of Pathology, Rambam Medical Center, 6 Ha’Aliya Street, P.O. Box 9602, Haifa 31096, Israel
    • Technion-Faculty of Medicine, P.O. Box 9649, Haifa 31096, Israel
  • ,
  • Rafi M. Nagler

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Rambam Medical Center, 6 Ha’Aliya Street, P.O. Box 9602, Haifa 31096, Israel
    • Technion-Faculty of Medicine, P.O. Box 9649, Haifa 31096, Israel

Received 23 February 2009; received in revised form 7 July 2009; accepted 8 July 2009. published online 03 September 2009.

Summary 

The classification system for malignant salivary gland tumors (MST) is largely dependent on its histogenesis. The histogenesis is uncertain but the “bicellular theory of origin” has been accepted by most and states that malignant transformation of reserve cells from either the intercalated or excretory duct are responsible for the development of MST. Cyclooxygenase-2 (cox-2), a potential molecular marker for MST, was analyzed on a series (n=56) of MST with the aim of determining the morphological MST subtypes capable of cox-2 overexpression and correlating its expression with histogenesis.

Fifty six primary major and minor gland MST were stained with anti-cox-2 antibody and rated with a combined score that added a scale of intensity to the percentage of tumor cells that overexpressed the cox-2 protein. A score of <3: negligible or negative staining; score of 4–5; moderate staining; score of 6–7; strong staining. Tumor types were segregated by morphology, histological features and proposed histogenesis.

Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%). Primary squamous cell carcinoma (PSCC) was the exception. Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma. Strong cox-2 overexpression was noted in the epidermoid cells of MEC, abluminal duct cells surrounding the duct-like structures and ductal cells of AdC nos and salivary duct carcinoma. Myoepithelial and acinar cells were unreactive.

Although preliminary, the results of our study support the concept that MST of proposed excretory duct origin share a common histogenesis. Negligible cox-2 expression in PSCC may provide a useful tool for diagnosing the often histologically indistinguishable cases of high grade MEC. Follow-up studies on a larger series of MST are warranted.

Keywords: Cyclooxygenase-2 (cox-2), Oral cancer, Salivary gland, Malignant salivary gland tumors, Histogenesis, Molecular markers

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(09)00851-3

doi:10.1016/j.oraloncology.2009.07.016

Oral Oncology
Volume 45, Issue 12 , Pages 1044-1050, December 2009